Mid-term outcomes of percutaneous pulmonary valve replacement with Edwards-Sapien bioprosthesis in native right ventricular outflow tract
Belahnech, Yassin (Hospital Universitari Vall d'Hebron)
Martí-Aguasca, Gerard (Hospital Universitari Vall d'Hebron)
Dos Subira, Laura (Hospital Universitari Vall d'Hebron)
Betrián-Blasco, Pedro (Hospital Universitari Vall d'Hebron)
García del Blanco, Bruno (Hospital Universitari Vall d'Hebron)
Calvo-Barceló, Maria (Hospital Universitari Vall d'Hebron)
Ródenas-Alesina, Eduard (Hospital Universitari Vall d'Hebron)
Pijuan-Domènech, Antonia (Hospital Universitari Vall d'Hebron)
Gran, Ferran (Hospital Universitari Vall d'Hebron)
Ferrer Menduiña, Queralt (Hospital Universitari Vall d'Hebron)
Giralt-García, Gemma (Hospital Universitari Vall d'Hebron)
Miranda, Berta (Hospital Universitari Vall d'Hebron)
Gordon, Blanca (Hospital de la Santa Creu i Sant Pau (Barcelona, Catalunya))
González-Fernández, Víctor (Hospital Universitari Vall d'Hebron)
Barrabés, José A. (Hospital Universitari Vall d'Hebron)
Roses-Noguer, Ferran (Hospital Universitari Vall d'Hebron)
Ferreira-Gonzalez, Ignacio (Hospital Universitari Vall d'Hebron)

Data:	2025
Resum:	Information on mid-term outcomes of percutaneous pulmonary valve replacement (PPVR) with the Edwards Sapien (ES) valve in the native right ventricular outflow tract (RVOT) are limited. This study assesses mid-term outcomes in 76 patients who underwent PPVR between 2016 and 2022, comparing native (40. 8%) and non-native (59. 2%) RVOTs. The primary endpoint was a composite of endocarditis, reinterventions, and cardiovascular death and secondary outcomes included prosthetic valve dysfunction (PVD), tricuspid regurgitation (TR), right ventricular ejection fraction (RVEF), and indexed ventricular volumes. The median patient age was 23. 9 years. Pulmonary regurgitation was predominant in the native RVOT group (67. 7%), while pulmonary stenosis or combined lesions were more common in the non-native group (90. 9%). Procedural success was 98. 7%. After a median follow-up of 3. 3 years, there was no significant difference in freedom from the primary outcome between groups (87. 1% native vs. 93. 1% non-native, p = 0. 875). Endocarditis and reinterventions occurred at 1. 2 per 100 patient-years, and PVD at 3. 19 per 100 patient-years, with no differences between groups. A 1-year reduction in ventricular volumes and TR was seen only in the non-native group, with no improvement in RVEF. Overall, PPVR with the ES valve demonstrates satisfactory mid-term outcomes in both native and non-native RVOTs.
Drets:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, i la comunicació pública de l'obra, sempre que no sigui amb finalitats comercials, i sempre que es reconegui l'autoria de l'obra original. No es permet la creació d'obres derivades.
Llengua:	Anglès
Document:	Article ; recerca ; Versió publicada
Matèria:	Cardiology ; Congenital heart disease ; Edwards Sapien ; Interventional cardiology ; Percutaneous pulmonary valve replacement ; Pulmonary valve
Publicat a:	Scientific reports, Vol. 15 (February 2025) , art. 3977, ISSN 2045-2322

DOI: 10.1038/s41598-024-82336-4
PMID: 39893235

11 p, 3.9 MB

El registre apareix a les col·leccions:
Articles > Articles de recerca
Articles > Articles publicats